Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Retained Earnings: 2021-2025

Historic Retained Earnings for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to -$253.3 million.

  • ARS Pharmaceuticals' Retained Earnings fell 46.20% to -$253.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.3 million, marking a year-over-year decrease of 46.20%. This contributed to the annual value of -$123.3 million for FY2024, which is 6.09% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Retained Earnings stood at -$253.3 million for Q3 2025, which was down 25.31% from -$202.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Retained Earnings' 5-year high stood at -$42.3 million during Q4 2021, with a 5-year trough of -$253.3 million in Q3 2025.
  • Over the past 3 years, ARS Pharmaceuticals' median Retained Earnings value was -$141.6 million (recorded in 2024), while the average stood at -$151.0 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Retained Earnings tumbled by 82.39% in 2022, and later spiked by 56.41% in 2023.
  • ARS Pharmaceuticals' Retained Earnings (Quarterly) stood at -$42.3 million in 2021, then crashed by 82.08% to -$76.9 million in 2022, then tumbled by 70.66% to -$131.3 million in 2023, then increased by 6.09% to -$123.3 million in 2024, then tumbled by 46.20% to -$253.3 million in 2025.
  • Its Retained Earnings was -$253.3 million in Q3 2025, compared to -$202.1 million in Q2 2025 and -$157.2 million in Q1 2025.